Nektar 18-214-10- A Phase 2, Randomized, Non-Comparative, Open-Label Study Of Nktr-214 In Combination With Nivolumab And Of Chemotherapy In Cisplatin Ineligible, Locally Advanced Or Metastatic Urothelial Cancer Patients With Low Pd-L1 Expression
Posted Date: Feb 24, 2020
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to evaluate the anti-tumor activity of NKTR-214 in combination with nivolumab by assessing the ORR by RECIST 1.1 per blinded independent central review (BICR) in patients whose tumors have low PD-L1 expression
Criteria:
To Be Eligible: Must Have Documented Urothelial Cell Carcinoma, Ecog = 2, Measurable Disease, Prior Systemic Chemotherapy Or Investigational Agent For Study Cancer, No Other Active Malignancy Within 3 Years
Keywords:
Urothelial Cancer, Oncology, Gu
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com